Evotec stock extends losses as guidance cut weighs on sentiment
Published on 09/11/2026 at 14:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock (ISIN DE0005664809) remains under pressure, with the biotechnology group trading close to a new 52-week low around EUR 3.00 on Xetra on September 11, 2026, following a sharp downgrade of its 2026 outlook earlier in the summer.
Evotec shares hover near 52-week low
According to price data from the Xetra session on September 11, 2026, Evotec shares recently changed hands around EUR 3.02, down about 0.9 percent from the prior close, with an intraday low of EUR 2.97 marking a fresh 52-week trough for the stock and an opening level near EUR 3.05 giving way quickly to selling pressure.
The same Xetra overview shows a 52-week high of EUR 7.30 reached on October 27, 2025, meaning that at a price of about EUR 3.02 on September 11, 2026, Evotec stock is trading more than 58 percent below that recent high, underlining how severely the shares have re-rated since late 2025.
Guidance cut and half-year 2026 figures
The main reason for the weak share price lies in Evotec’s revised outlook for the current year. As Ad-hoc-news reports, Evotec cut its 2026 revenue guidance from a previous range of EUR 700 million to EUR 780 million to a reduced corridor of EUR 570 million to EUR 610 million, while the projected adjusted EBITDA loss widened from an earlier band of EUR 0 million to EUR 40 million to a significantly larger expected loss of EUR 70 million to EUR 105 million.
According to the same analysis from Ad-hoc-news on September 10, 2026, the half-year 2026 report confirmed the weaker trajectory: first-half 2026 revenue fell 19.2 percent to EUR 300.1 million, while adjusted EBITDA came in at minus EUR 42.7 million, signaling that the company is already loss-making on an adjusted basis midway through the year.
A separate overview on Ad-hoc-news notes that the guidance downgrade announced in mid-July 2026 continues to function as the key reference point for investors, with subsequent partnership news and operational progress judged against the backdrop of lower revenue expectations and a deeper anticipated loss.
Analyst and market reaction remains cautious
The cautious stance in the market is also visible in broker commentary. As Trading-Treff reported on September 10, 2026, several brokers currently rate Evotec shares only at Hold on balance, with no major positive price target revisions in recent weeks, reflecting the uncertainty created by the reduced 2026 guidance and the negative adjusted EBITDA outlook.
The same article from Trading-Treff highlights that the share price has fallen by around 7.0 percent over a period of several weeks, with Evotec stock recently quoted at about EUR 3.06 and only roughly 1.9 percent above a 52-week low near EUR 3.00, while the distance to a year high of EUR 7.75 reached in November of the previous year amounts to approximately 61 percent.
Stock price and trading data
Per Xetra data for Evotec SE (ticker EVT) on September 10, 2026, the stock started that session at EUR 3.16, slipped intraday to as low as EUR 2.99 and eventually closed at EUR 3.04 at 17:35 CET, representing a 3.0 percent decline compared with the prior closing price of EUR 3.14 based on quote tables at Finanzen.net, and setting the fresh 52-week low at EUR 2.99 that continues to anchor the chart picture into September 11, 2026.
Evotec stock key data
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Xetra
- Price (as of September 10, 2026, 17:35): 3.04 EUR
- Market capitalization: [value] [currency] (as of [date])
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: MDAX
